Breast MR with special focus on DW-MRI and DCE-MRI

Cancer Imaging

Volumn 11, Issue 1, 2011, Pages 76-90

  Petralia, Giuseppe ^a   Bonello, L ^b   Priolo, F ^a   Summers, P ^a   Bellomi, M ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

BI RADS; Breast cancer; Breast mri; Diffusion weighted mri; Dynamic contrast enhanced mri

Indexed keywords

BREAST CARCINOMA; BREAST LESION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PATIENT MONITORING; POSTOPERATIVE PERIOD; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR VOLUME;

BREAST; BREAST NEOPLASMS; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING;

EID: 79960542140     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.0014     Document Type: Review

References (47)

1. BI-RADS® Atlas. American College of Radiology. http://www.acr.org/ SecondaryMainMenuCategories/quality-safety/BIRADSAtlas/BIRADSAtlasexcerptedtext. aspx. Accessed 20th February 2011.
2. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.
3. Sinha S, Lucas-Quesada FA, Sinha U, DeBruhl N, Bassett LW. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging 2002; 15: 693-704. doi:10.1002/jmri.10116.
4. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 2010; 46: 1296-316. doi:10.1016/j.ejca.2010.02.015.
5. Sardanelli F, Fausto A, Menicagli L, Esseridou A. Breast vascular mapping obtained with contrast-enhanced MR imaging: implications for cancer diagnosis, treatment, and risk stratification. Eur Radiol 2007; 17(Suppl 6), F48-51.
6. Morris EA. Breast magnetic imaging lexicon. In: Morris EA, Liberman L, editors. Breast MRI diagnosis and intervention. New York: Springer; 2005.
7. Tominaga J, Hama H, Kimura N, Takahashi S. MR imaging of medullary carcinoma of the breast. Eur J Radiol 2009; 70: 525-9. doi:10.1016/j.ejrad.2008. 01.044.
8. Kuhl CK, Klaschik S, Mielcarek P, Gieseke J, Wardelmann E, Schild HH. Do T2 weighted pulse sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? J Magn Reson Imaging 1999; 9: 187-96. doi:10.1002/(SICI)1522-2586(199902)9:2〈187::AID-JMRI6〉3.0.CO;2-2.
9. Malich A, Fischer DR, Wurdinger S, et al. Potential MRI interpretation model: differentiation of benign from malignant breast masses. AJR Am J Roentgenol 2005; 185: 964-70. doi:10.2214/AJR.04.1073.
10. Tse GM, Law BK, Ma TK, et al. Hamartoma of the breast: a clinicopathological review. J Clin Pathol 2002; 55: 951-4. doi:10.1136/jcp.55. 12.951. (Pubitemid 35454500)
11. Morris EA. Diagnostic breast MR imaging: current status and future directions. Magn Reson Imaging Clin N Am 2010; 18: 57-74. doi:10.1016/j.mric. 2009.09.005.
12. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000; 217: 841-8.
13. Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 2003; 13: 2425-35. (Pubitemid 37407473)
14. Nunes LW, Schnall MD, Orel SG. Update of breast MR imaging architectural interpretation model. Radiology 2001; 219: 484-94. (Pubitemid 32336366)
15. Erguvan-Dogan B, Whitman GJ, Kushwaha AC, Phelps MJ, Dempsey PJ. BI-RADS-MRI: a primer. AJR Am J Roentgenol 2006; 187: W152-60. doi:10.2214/AJR.05.0572.
16. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-10.
17. Kuhl CK. Concepts for differential diagnosis in breast MR imaging. Magn Reson Imaging Clin N Am 2006; 14: 305-28. doi:10.1016/j.mric.2006.07.002. (Pubitemid 46053826)
18. Cilotti A, Nori J, Panizza P. Come si interpreta. In: Giuseppetti GM, Panizza P, Valeri G, editors. Risonanza magnetica mammaria, istruzioni per l'uso. Vermezzo, Milan: Poletto Editore srl; 2009.
19. Baum F, Fischer U, Vosshenrich R, Grabbe E. Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 2002; 12: 1087-92.
20. Chen JH, Nalcioglu O, Su MY. Fibrocystic change of the breast presenting as a focal lesion mimicking breast cancer in MR imaging. J Magn Reson Imaging 2008; 28: 1499-505. doi:10.1002/jmri.21455.
21. Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006; 239: 351-60. doi:10.1148/radiol. 2392050205.
22. Oshida K, Nagashima T, Ueda T, et al. Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. Eur Radiol 2005; 15: 1353-60. doi:10.1007/s00330-005-2661-9. (Pubitemid 40983517)
23. Li J, Yu Y, Zhang Y, et al. A clinically feasible method to estimate pharmacokinetic parameters in breast cancer. Med Phys 2009; 36: 3786-94. doi:10.1118/1.3152113.
24. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-35. doi:10.1148/radiol.2443060926. (Pubitemid 47292083)
25. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-77. doi:10.1200/JCO.2005.03.4645. (Pubitemid 46622044)
26. Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 2003; 13: 80-7. (Pubitemid 36790494)
27. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-9. doi:10.1158/1078-0432.CCR-07-4310.
28. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002; 15: 154-63. doi:10.1002/nbm.756. (Pubitemid 34213405)
29. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-93. (Pubitemid 34778087)
30. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7: 496-501. (Pubitemid 351847022)
31. Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M. Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci 2007; 6: 21-7. doi:10.2463/mrms.6.21.
32. Fornasa F, Pinali L, Gasparini A, Toniolli E, Montemezzi S. Diffusion-weighted magnetic resonance imaging in focal breast lesions: analysis of 78 cases with pathological correlation. Radiol Med 2011; 116: 264-75. doi:10.1007/s11547-010-0602-4.
33. Kuroki Y, Nasu K, Kuroki S, et al. Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. Magn Reson Med Sci 2004; 15: 79-85.
34. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16: 172-8. doi:10.1002/jmri.10140. (Pubitemid 34810055)
35. Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006; 24: 319-24. doi:10.1002/jmri.20643. (Pubitemid 44188557)
36. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH. The role of diffusion- weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol 2007; 8: 390-6. doi:10.3348/kjr.2007.8.5.390.
37. Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol 2007; 17: 2646-55. doi:10.1007/s00330-007-0621-2.
38. Hatakenaka M, Soeda H, Yabuuchi H, et al. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci 2008; 7: 23-29. doi:10.2463/mrms.7.23.
39. Tsushima Y, Takahashi-Taketomi A, Endo K. Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. Magn Reson Imaging 2009; 30: 249-55.
40. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32: 2-16. doi:10.1002/jmri.22167.
41. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-13. doi:10.1002/nbm.1245.
42. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-7. doi:10.1016/j.mri.2005.11.005. (Pubitemid 44205378)
43. Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusionweighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 2010; 254: 357-66. doi:10.1148/radiol.2542090405.
44. Iacconi C, Giannelli M, Marini C, et al. The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study. Eur Radiol 2010; 20: 303-8. doi:10.1007/s00330-009-1550-z.
45. Park SH, Moon WK, Cho N, Song IC, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63. doi:10.1148/radiol.10092021.
46. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505.
47. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891-9. (Pubitemid 30262836)